This content is machine translated MASLD/MASH Drug therapy options on the rise: spectacular evidence Over the last few decades, the incidence of steatotic liver disease has risen in parallel with the increase in obesity, diabetes and other metabolic diseases. It is recommended to screen...…
View Post 7 min This content is machine translated Steatotic liver disease GLP-1RA in MASH – what’s new? Metabolic dysfunction-associated steatohepatitis (MASH) corresponds tothe liver disease formerly known as non-alcoholic fatty liver inflammation (NASH). The most common causes of MASH are obesity and diabetes. There are still no...…
